Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesThe stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer's disease
Acta Neurologica Scandinavica, 09/28/09
Wiig EH et al. – AQT processing speed, ADAS–Cog, and MMSE measures proved stable during the second 6 months of treatment with AChEI.
Elisabeth H. Wiig Ph.D., 10/14/09
| The clinical implications of this research appears related to the finding that AQT showed appropriate levels of stability, equal to those of ADAS-Cog, for measuring responsiveness to CNS medication for Alzheimer's disease (AD). This suggests that AQT may be used in clinical practice to differentiate responders and non-responders to CNS medication that affects the central executive that controls attention, memory and cognitive flexibility (i.e., set shifting). Such clinical applications may prove valid beyond AD and appropriate in the medical treatment of other executive function disorders (e.g., ADHD, Tourette Spectrum Syndrome). Future research and clinical applications should clarify these questions. |
Related Articles
Does Diabetes Speed Up Memory Loss In Alzheimers Disease?
ScienceDaily, 10/28/09
Relevance Score: 71%
High Blood Pressure Likely in Alzheimers Offspring
MedLinePlus, 11/04/09
Relevance Score: 70%
Activated astrocytes: a therapeutic target in Alzheimer's disease?
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 69%
Protective Role For Copper In Alzheimers Disease
ScienceDaily, 10/14/09
Relevance Score: 69%
All-trans retinoic acid as a novel therapeutic strategy for Alzheimer's disease
Expert Review of Neurotherapeutics, 11/19/09
Relevance Score: 68%
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy
Journal of Neuro-Oncology, 12/04/09
Combination therapy of 17(beta)-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke
Journal of Pharmacology and Experimental Therapeutics, 12/04/09
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: Too little juice or a miswired brain
Molecular Pharmacology, 12/04/09
Sponsor
Article Search
Sponsor